Clinical trial
Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer
NCT00498225 · Taiho Pharmaceutical Co., Ltd., Industry · Completed
Key facts
| NCT number | NCT00498225 |
|---|---|
| Title | Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer |
| Official title | Randomized Phase III Study of Gemcitabine Versus TS-1 Versus Gemcitabine Plus TS-1 in Unresectable Advanced Pancreatic Cancer (With Local Progression or Metastasis) |
| Acronym | GEST |
| Lead sponsor | Taiho Pharmaceutical Co., Ltd., Industry |
| Collaborators | TTY Biopharm Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine plus TS-1, TS-1, Gemcitabine |
| Enrollment | 834 |
| Start date | Jul 1, 2007 |
| Primary completion | Jul 1, 2011 |
| Completion | Jun 1, 2012 |
| First posted | Jul 9, 2007 |
| Last update posted | Nov 2, 2012 |
| Countries | Japan, Taiwan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: